Phibro Animal Health

Asia And Latin America Will Drive Secular Animal Health Demand

AnalystHighTarget

Not Invested

Consensus Narrative from 4 Analysts

Published

01 Jun 25

AnalystHighTarget's Fair Value

US$45.00

12.2% undervalued

10 Sep

US$39.53

83.6%

0.3%

83.6%

0.3%

Edit anytime before Jun 1 11:01 PM. Then post Updates to your followers.

Author's Valuation

US$45.0

12.2% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$45

12.2% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

5.64%

Pharma revenue growth rate

0.60%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.78%

Calculation

US$123.62m

Earnings '28

17.73x

PE Ratio '28

US$2.19b

Market Cap '28

US$2.19b

Market Cap '28

40.62m

No. shares '28

US$53.94

Share Price '28

US$53.94 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$44.31

Fair Value '25